Recent Trials in AD – Inconsistency Between Outcome Scales

Time: 11:55 am
day: Day One Clinical Track AM

Details:

  • Decreasing EASI baseline severity in recent years AD trial has led to very high placebo responses – Particularly in the moderate patient segment
  • IGA and PGIC remain robust endpoints
  • What can we learn, and can Biomarkers help substantiate which scale is the most appropriate
  • Going forward – How do we face the EASI “Challenge” – better training, higher baseline severity, better monitoring

Speakers:

Kim Kjoeller